SCHEMBL23927271

SCHEMBL23927271

O=C(O)Nc1c(C(F)(F)F)csc1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.36
ANO1 Q5XXA6 1/20 0.34
HPGD P15428 1/20 0.33
MAPK8 P45983 1/20 0.33
MAPK10 P53779 1/20 0.33
KMT2A Q03164 1/20 0.33
RAB9A P51151 2/20 0.33
PDK1 Q15118 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
GPR35 Q9HC97 1/20 0.33
CLCN2 P51788 1/20 0.32
GRM4 Q14833 1/20 0.32
TRPV1 Q8NER1 1/20 0.31
GRIK1 P39086 1/20 0.31
TMPRSS4 Q9NRS4 1/20 0.31
PTGS2 P35354 1/20 0.31
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23960262 0.79 LMNA (0.42) HPGDLMNA
SCHEMBL21875055 0.74 KMT2A (0.45) KMT2ARAB9ACYP1A2CYP2C19MAPT
SCHEMBL23927243 0.73 ANO1 (0.39) KDRANO1HPGDCLCN2
SCHEMBL23927258 0.72 KMT2A (0.33) KMT2A
SCHEMBL23927263 0.72 KEAP1 (0.30) HPGDKMT2AMAPTSMN1; SMN2LMNA
SCHEMBL23927261 0.70 CYP2A6 (0.32) HPGDKMT2AMAPTSMN1; SMN2LMNA
SCHEMBL5237466 0.70 PDK1 (0.38) ANO1KMT2ARAB9APDK1MAPT
SCHEMBL23927233 0.70 CYP2A6 (0.31) KMT2A
SCHEMBL23927255 0.68 NOTUM (0.40) HPGDMAPK8MAPK10KMT2AMAPT
SCHEMBL5234643 0.68 PDK1 (0.42) ANO1KMT2ARAB9APDK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348453-A1 HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2023-11-02 US disclosed
EP-4139305-A1 HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF iOmx Therapeutics AG (DE) 2023-03-01 EP disclosed
WO-2021214117-A1 HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2021-10-28 WO disclosed
EP-3901151-A1 HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF iOmx Therapeutics AG (DE) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348453-A1 HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF ABL1, PRKDC, PRKACA KDR 784/4885ANO1 4693/4885HPGD 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.